Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.386
A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo
drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.
{"title":"4CPS-050 Use of galcanezumab in patients with migraine in a tertiary hospital: health results","authors":"A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo","doi":"10.1136/ejhpharm-2022-eahp.386","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.386","url":null,"abstract":"drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126261926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.431
R. Castillejo, J. Cordero, M. Romero-González, A. Martinez-Suarez
Background and importanceAs of December 2019, the world is facing a pandemic caused by the SARS-CoV-2 coronavirus (COVID-19). Symptoms resulting from the infection vary widely, ranging from asymptomatic disease to pneumonia and life-threatening complications.Aim and objectivesThe aim was to study the impact of the active oncohaematological process on the severity and short-medium term mortality of COVID-19 infection.Material and methodsObservational retrospective study, carried out in a Spanish tertiary-level hospital. All patients diagnosed with COVID-19 and hospital admission between March 2020 and June 2021 were included. Variables collected were demographics, comorbidities;situation during hospitalisation (defining severe situation as admission to intensive care unit (ICU) or intubation) and mortality at 14 and 30 days after hospital admission. Data were obtained through the digital medical record and managed by R software (V.4–2021).ResultsWe included 1924 patients in the non-oncological group, 47.5% (915) men with a median age of 67 years and interquartile range (IQR) of 53–77. 128 patients (6.23%) were included in the active oncohaematological group, 58.6% were men (median age 72 (IQR 63–78) years). The most prevalent oncohaematological processes were: lung cancer (16.4%), colorectal (15.6%), bladder (10.9%), breast (10.2%) and prostate (8.59%). Metastases were present in 42.2% of patients. The main comorbidities presented by oncohaematological patients with statistical significance versus non-oncological patients were diabetes mellitus (30.5% vs 19.4%), dyslipidaemia (46.9% vs 32.2%), hypertension (52.3% vs 42.0%), chronic renal failure (18.0% vs 8.73%), chronic obstructive pulmonary disease (22.7% vs 9.94%), obesity (14.1% vs 15.2%) and heart failure (13.3% vs 10.6%). In the oncohaematological group, 44.5% were in a serious condition during their admission. The number who died compared to non-oncohaematological patients was 23.4% versus 13.6% at day 14 and 29.7% versus 18.1% at day 30. The two main neoplasms in the deceased patients were lung cancer (26.3%) and colorectal cancer (21%). Univariate analysis showed a relative risk of 1.72 (1.23–2.4) and 1.64 (1.23–2.17) mortality at 14 and 30 days, respectively, for COVID-19 in patients with active oncohematological processes versus non-oncohematological processes.Conclusion and relevanceThe data reflect a higher mortality at 14 and 30 days due to COVID-19 in the oncohaematological population (72% and 64%, respectively). The oncohaematological population has a higher percentage of comorbidities associated with the total that may also influence this increased risk of mortality.References and/or acknowledgementsConflict of interestNo conflict of interest
背景及重要性截至2019年12月，世界正面临由新冠肺炎(COVID-19)引起的大流行。感染引起的症状差别很大，从无症状疾病到肺炎和危及生命的并发症。目的和目的研究活动性肿瘤血液学过程对COVID-19感染严重程度和中短期死亡率的影响。材料与方法观察性回顾性研究，在西班牙一家三级医院进行。所有在2020年3月至2021年6月期间被诊断为COVID-19并住院的患者都被纳入其中。收集的变量包括人口统计学、合并症、住院期间的情况(将严重情况定义为入住重症监护病房(ICU)或插管)以及入院后14天和30天的死亡率。数据通过数字病历获取，并由R软件(V.4-2021)管理。结果我们纳入了1924例非肿瘤组患者，其中47.5%(915例)为男性，中位年龄为67岁，四分位间距(IQR)为53-77。活动性血液肿瘤组128例(6.23%)，58.6%为男性(中位年龄72岁(IQR 63-78)岁)。最常见的肿瘤血液学病变为:肺癌(16.4%)、结直肠癌(15.6%)、膀胱癌(10.9%)、乳腺癌(10.2%)和前列腺癌(8.59%)。42.2%的患者存在转移。与非肿瘤患者相比，血液肿瘤患者出现的主要合并症为糖尿病(30.5% vs 19.4%)、血脂异常(46.9% vs 32.2%)、高血压(52.3% vs 42.0%)、慢性肾功能衰竭(18.0% vs 8.73%)、慢性阻塞性肺疾病(22.7% vs 9.94%)、肥胖(14.1% vs 15.2%)和心力衰竭(13.3% vs 10.6%)。在血液肿瘤组中，44.5%的患者入院时病情严重。与非血液肿瘤患者相比，第14天和第30天的死亡人数分别为23.4%和13.6%和29.7%和18.1%。死亡患者的两种主要肿瘤是肺癌(26.3%)和结直肠癌(21%)。单因素分析显示，活动性血液肿瘤过程患者与非血液肿瘤过程患者在14天和30天死亡的相对风险分别为1.72(1.23-2.4)和1.64(1.23-2.17)。数据显示，在血液肿瘤患者中，COVID-19在14天和30天的死亡率较高(分别为72%和64%)。血液病人群的合并症比例较高，这也可能影响死亡风险的增加。参考文献和/或致谢利益冲突无利益冲突
{"title":"6ER-013 Analysis of patients’ mortality in SARS-CoV-2 infection during the first month of hospital admission","authors":"R. Castillejo, J. Cordero, M. Romero-González, A. Martinez-Suarez","doi":"10.1136/ejhpharm-2022-eahp.431","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.431","url":null,"abstract":"Background and importanceAs of December 2019, the world is facing a pandemic caused by the SARS-CoV-2 coronavirus (COVID-19). Symptoms resulting from the infection vary widely, ranging from asymptomatic disease to pneumonia and life-threatening complications.Aim and objectivesThe aim was to study the impact of the active oncohaematological process on the severity and short-medium term mortality of COVID-19 infection.Material and methodsObservational retrospective study, carried out in a Spanish tertiary-level hospital. All patients diagnosed with COVID-19 and hospital admission between March 2020 and June 2021 were included. Variables collected were demographics, comorbidities;situation during hospitalisation (defining severe situation as admission to intensive care unit (ICU) or intubation) and mortality at 14 and 30 days after hospital admission. Data were obtained through the digital medical record and managed by R software (V.4–2021).ResultsWe included 1924 patients in the non-oncological group, 47.5% (915) men with a median age of 67 years and interquartile range (IQR) of 53–77. 128 patients (6.23%) were included in the active oncohaematological group, 58.6% were men (median age 72 (IQR 63–78) years). The most prevalent oncohaematological processes were: lung cancer (16.4%), colorectal (15.6%), bladder (10.9%), breast (10.2%) and prostate (8.59%). Metastases were present in 42.2% of patients. The main comorbidities presented by oncohaematological patients with statistical significance versus non-oncological patients were diabetes mellitus (30.5% vs 19.4%), dyslipidaemia (46.9% vs 32.2%), hypertension (52.3% vs 42.0%), chronic renal failure (18.0% vs 8.73%), chronic obstructive pulmonary disease (22.7% vs 9.94%), obesity (14.1% vs 15.2%) and heart failure (13.3% vs 10.6%). In the oncohaematological group, 44.5% were in a serious condition during their admission. The number who died compared to non-oncohaematological patients was 23.4% versus 13.6% at day 14 and 29.7% versus 18.1% at day 30. The two main neoplasms in the deceased patients were lung cancer (26.3%) and colorectal cancer (21%). Univariate analysis showed a relative risk of 1.72 (1.23–2.4) and 1.64 (1.23–2.17) mortality at 14 and 30 days, respectively, for COVID-19 in patients with active oncohematological processes versus non-oncohematological processes.Conclusion and relevanceThe data reflect a higher mortality at 14 and 30 days due to COVID-19 in the oncohaematological population (72% and 64%, respectively). The oncohaematological population has a higher percentage of comorbidities associated with the total that may also influence this increased risk of mortality.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114827732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.412
E. Gonzalez Colominas, M. De Antonio Cuscó, M. Masip Torne, M. Martin, G. Cardona, M. Comas, Mathieu Roch, B. Lopez, FI Torres, A. Retamero, P. Luque
{"title":"4CPS-255 Frequency of consumption of complementary and alternative medicine among HIV patients: a multicentre cross-sectional study","authors":"E. Gonzalez Colominas, M. De Antonio Cuscó, M. Masip Torne, M. Martin, G. Cardona, M. Comas, Mathieu Roch, B. Lopez, FI Torres, A. Retamero, P. Luque","doi":"10.1136/ejhpharm-2022-eahp.412","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.412","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121849133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.421
A. Gracia Moya, C. Varon Galcera, I. Cardona Pascual, E. Florensa Royo, J. Vidal Otero, G. Vancells Lujan, M. G. Gorgas Torner
{"title":"5PSQ-071 Real-world results of effectiveness and security of erenumab and galcanezumab in migraine patients","authors":"A. Gracia Moya, C. Varon Galcera, I. Cardona Pascual, E. Florensa Royo, J. Vidal Otero, G. Vancells Lujan, M. G. Gorgas Torner","doi":"10.1136/ejhpharm-2022-eahp.421","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.421","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116395223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.380
Y. Dhif, P. Bonnabry, A. Diana
Background and importanceVaccine hesitancy is one of the top 10 threats to global health according to the World Health Organization.1 A part of the Swiss population is hesitant to vaccinate against COVID-19.2Aim and objectivesThe aim of this study was to conduct a public health action with hesitant to vaccination and measure its impact on vaccine hesitancy and on vaccination rate.Material and methodsVaccine hesitancy and barriers to vaccination were measured and identified using a pre-test questionnaire. Only non-vaccinated volunteer participants were included, and they were invited to a 1-hour online session using motivational interviewing techniques, animated by a physician and a pharmacist. Two weeks after the session, they were asked to fill a post-test and 2 months later, their vaccine status was requested. Data collection was conducted from April to August 2021.Results31 adults participated for a total of 11 online sessions (2.8 participants/session). Majority were women (68%, n=21) and aged between 35 and 60 years (71%). 10 (32.3%) were public health professionals and 21 (67.7%) were not. Prior to the study, 54.9% did not consider vaccines safe (19.4% post-study), 87.1% were concerned about vaccine side effects (64.5% post-study) and 51.6% considered vaccines to be effective (83.9% post-study). Before the study, participants were classified as certainly willing to vaccinate (3.2%), probably (9.7%), probably not (35.5%), certainly not (12.9%), do not know/other (38.8%) and the degree of confidence in vaccination was 4.5 ± 2.2 (scale 1–10). After the study, the confidence increased to 6.3 ± 2.4 (+29%). Following the study, 52% (n=14) were effectively vaccinated. Among reasons that motivated to vaccinate: vaccination will help with containing the pandemic (5/14) and benefit-risk ratio is positive for the vaccine (5/14). 48% (n=13) were not vaccinated mainly for the following reasons: doubt about the effectiveness (2/13) and fear of side effects (2/13). Opinion on vaccines was moved mainly by having personal questions answered and feeling not judged for having a different opinion on vaccination.Conclusion and relevanceIn this study we could reduce vaccine hesitancy by increasing the degree of confidence in the vaccine and our action effectively convinced half the participants to get vaccinated.References and/or acknowledgements1. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-20192. https://sotomo.ch/site/wp-content/uploads/2021/02/6.-SRG-Corona-Monitor.pdfConflict of interestNo conflict of interest
{"title":"4CPS-022 To vaccinate or not to vaccinate: impact of a public health action on vaccine hesitancy","authors":"Y. Dhif, P. Bonnabry, A. Diana","doi":"10.1136/ejhpharm-2022-eahp.380","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.380","url":null,"abstract":"Background and importanceVaccine hesitancy is one of the top 10 threats to global health according to the World Health Organization.1 A part of the Swiss population is hesitant to vaccinate against COVID-19.2Aim and objectivesThe aim of this study was to conduct a public health action with hesitant to vaccination and measure its impact on vaccine hesitancy and on vaccination rate.Material and methodsVaccine hesitancy and barriers to vaccination were measured and identified using a pre-test questionnaire. Only non-vaccinated volunteer participants were included, and they were invited to a 1-hour online session using motivational interviewing techniques, animated by a physician and a pharmacist. Two weeks after the session, they were asked to fill a post-test and 2 months later, their vaccine status was requested. Data collection was conducted from April to August 2021.Results31 adults participated for a total of 11 online sessions (2.8 participants/session). Majority were women (68%, n=21) and aged between 35 and 60 years (71%). 10 (32.3%) were public health professionals and 21 (67.7%) were not. Prior to the study, 54.9% did not consider vaccines safe (19.4% post-study), 87.1% were concerned about vaccine side effects (64.5% post-study) and 51.6% considered vaccines to be effective (83.9% post-study). Before the study, participants were classified as certainly willing to vaccinate (3.2%), probably (9.7%), probably not (35.5%), certainly not (12.9%), do not know/other (38.8%) and the degree of confidence in vaccination was 4.5 ± 2.2 (scale 1–10). After the study, the confidence increased to 6.3 ± 2.4 (+29%). Following the study, 52% (n=14) were effectively vaccinated. Among reasons that motivated to vaccinate: vaccination will help with containing the pandemic (5/14) and benefit-risk ratio is positive for the vaccine (5/14). 48% (n=13) were not vaccinated mainly for the following reasons: doubt about the effectiveness (2/13) and fear of side effects (2/13). Opinion on vaccines was moved mainly by having personal questions answered and feeling not judged for having a different opinion on vaccination.Conclusion and relevanceIn this study we could reduce vaccine hesitancy by increasing the degree of confidence in the vaccine and our action effectively convinced half the participants to get vaccinated.References and/or acknowledgements1. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-20192. https://sotomo.ch/site/wp-content/uploads/2021/02/6.-SRG-Corona-Monitor.pdfConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130986035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.396
R. Rodríguez Mauriz, L. Borràs Trias, N. García Farre, N. Almendros-Abad, N. Rudi Sola
{"title":"4CPS-130 Analysis of the different cardioversion strategies in the emergency department in a secondary hospital","authors":"R. Rodríguez Mauriz, L. Borràs Trias, N. García Farre, N. Almendros-Abad, N. Rudi Sola","doi":"10.1136/ejhpharm-2022-eahp.396","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.396","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124438008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.384
S. Coenradie, C. Batenburg, M. De Graaf-Van Der Kort, P. Langendijk
Background and importance Serious medication errors can be made during unexpected hospital admittance through the emergency ward. In particular, anticoagulants portray a great risk for patients when proper medication reconciliation is absent.We started using pharmacy practitioners (PPs) to improve this process on the emergency ward. We report here the results of two case series with respect to accuracy in the medication reconciliation on the emergency room (ER) ward. Aim and objectives To investigate if appropriate embedding of PPs in the process of medication reconciliation during unexpected admittance to the hospital could lead to fewer medication errors downstream in other hospital wards. Material and methods A PP was embedded in the ER ward team during office hours (08:00 to 17:00) to perform the medication reconciliation of unexpectedly admitted patients instead of ER physicians. The two case series of admitted patients were chosen in a post-propter design. As a zero measurement, a case series of patients (ZMCS) in a pilot phase was used (October-December 2019). This pilot phase was done to collect data on hospital administration in order to show that PPs could be embedded to do this task. This retrospective dataset consisted of 40 patients, unexpectedly admitted on the ER ward and for whom the ER physicians performed the medication reconciliation. A prospective case series of patients was then performed during the period October-December 2020 under the same conditions and used as the experimental case series (EXCS) to compare with the ZMCS. The number of medication errors in the EXCS divided by the number of medication errors during the ZMCS was our main outcome parameter expressed as a percentage. After ER admittance patients were transmitted to several other specialist wards. Results Our results showed a 40% reduction in medication errors downstream in the specialist wards when the PPs were involved in the medication reconciliation process in the EXCS compared to the medication reconciliation done by ER physicians in the ZMCS. Conclusion and relevance We conclude that PPs can make a valuable contribution to reduce the number of medication errors downstream in the hospital when embedded in the ER ward team.
{"title":"4CPS-032 How to improve the appropriate prescription of anticoagulants during unexpected emergency room admittance to the hospital? A case series report using pharmacy practitioners","authors":"S. Coenradie, C. Batenburg, M. De Graaf-Van Der Kort, P. Langendijk","doi":"10.1136/ejhpharm-2022-eahp.384","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.384","url":null,"abstract":"Background and importance Serious medication errors can be made during unexpected hospital admittance through the emergency ward. In particular, anticoagulants portray a great risk for patients when proper medication reconciliation is absent.We started using pharmacy practitioners (PPs) to improve this process on the emergency ward. We report here the results of two case series with respect to accuracy in the medication reconciliation on the emergency room (ER) ward. Aim and objectives To investigate if appropriate embedding of PPs in the process of medication reconciliation during unexpected admittance to the hospital could lead to fewer medication errors downstream in other hospital wards. Material and methods A PP was embedded in the ER ward team during office hours (08:00 to 17:00) to perform the medication reconciliation of unexpectedly admitted patients instead of ER physicians. The two case series of admitted patients were chosen in a post-propter design. As a zero measurement, a case series of patients (ZMCS) in a pilot phase was used (October-December 2019). This pilot phase was done to collect data on hospital administration in order to show that PPs could be embedded to do this task. This retrospective dataset consisted of 40 patients, unexpectedly admitted on the ER ward and for whom the ER physicians performed the medication reconciliation. A prospective case series of patients was then performed during the period October-December 2020 under the same conditions and used as the experimental case series (EXCS) to compare with the ZMCS. The number of medication errors in the EXCS divided by the number of medication errors during the ZMCS was our main outcome parameter expressed as a percentage. After ER admittance patients were transmitted to several other specialist wards. Results Our results showed a 40% reduction in medication errors downstream in the specialist wards when the PPs were involved in the medication reconciliation process in the EXCS compared to the medication reconciliation done by ER physicians in the ZMCS. Conclusion and relevance We conclude that PPs can make a valuable contribution to reduce the number of medication errors downstream in the hospital when embedded in the ER ward team.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131564704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.381
I. Patier, N. Herranz-Muñoz, F. Fernandez Fraga, J. Sánchez-Rubio Ferrández, I. García-Bermejo, M. Moreno-García, T. Molina-García
{"title":"4CPS-025 Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab","authors":"I. Patier, N. Herranz-Muñoz, F. Fernandez Fraga, J. Sánchez-Rubio Ferrández, I. García-Bermejo, M. Moreno-García, T. Molina-García","doi":"10.1136/ejhpharm-2022-eahp.381","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.381","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"123 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114191624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.394
N. Herranz-Muñoz, J. Sánchez-Rubio Ferrández, L. Martín-Zaragoza, M. Gómez-Bermejo, S. Solís-Cuñado, T. Molina-García
{"title":"4CPS-126 Real-world persistence with fampridine among multiple sclerosis patients","authors":"N. Herranz-Muñoz, J. Sánchez-Rubio Ferrández, L. Martín-Zaragoza, M. Gómez-Bermejo, S. Solís-Cuñado, T. Molina-García","doi":"10.1136/ejhpharm-2022-eahp.394","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.394","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114823976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.400
L. Perez Cordon, A. Sánchez Ulayar, S. Marín Rubio, V. Aguilera Jimenez, L. Campins Bernadàs, J. Delgado Rodríguez, M. Bitlloch Obiols, R. Merino Méndez, T. Gurrera Roig, D. López Faixó
{"title":"4CPS-164 Durability of oral dual antiretroviral therapy in HIV patients","authors":"L. Perez Cordon, A. Sánchez Ulayar, S. Marín Rubio, V. Aguilera Jimenez, L. Campins Bernadàs, J. Delgado Rodríguez, M. Bitlloch Obiols, R. Merino Méndez, T. Gurrera Roig, D. López Faixó","doi":"10.1136/ejhpharm-2022-eahp.400","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.400","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115318634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：